ContextVision presents Q4 and full year 2016 report
(Thomson Reuters ONE) -
CONTEXTVISION SEES RECORD-BREAKING FOURTH QUARTER SALES
STOCKHOLM, Sweden - Feb. 23, 2017 - ContextVision, a world leading provider of
medical image processing software, saw record-breaking quarterly sales and is on
track to be a leader in image analysis for digital pathology.
Q4 2016 Performance
Sales for the fourth quarter reached a record of 24.9 MSEK. Annual revenue
reached 81.9 MSEK, which is the highest annual sales for the second year
running. The operating profit in the quarter was 2.9 MSEK (1.1 MSEK) and the
operating margin was 11.8 percent (5.9 percent), targeting future growth by
supporting research efforts.
"We are very pleased that we are able to generate profit whilst investing
significantly into research. The research program is developing very well,
positioning the company to become a leading medical technology company using
artificial intelligence," said ContextVision's CEO, Anita Tollstadius.
ContextVision saw strong sales in all regions during the fourth quarter,
especially in Asia, with a 38 percent increase compared to the same period in
2015. This was the eighth consecutive quarter of growth in the region.
Despite a comparatively higher cost for R&D, the company generated 2,9 MSEK in
profit and a positive cash flow. With research program contributions from
Eurostar, R&D costs were lower than the third quarter.
Recognized for our skills within artificial intelligence
"During the Radiological Society of North America (RSNA) meeting in Chicago this
past December, we focused our messaging on our latest development within
artificial intelligence and unveiled our new visual identity. We are well known
for our competence in image quality and are now being recognized for our skills
within artificial intelligence," said Tollstadius.
Entering product developing phase
ContextVision recruited new members to their team, adding new competence within
deep learning, immunology and regulatory affairs. The company also broadened
feasibility tests to include breast cancer in addition to prostate cancer, and
plans to enter the product development phase during the first half of 2017.
For further information, please contact ContextVision's CEO, Anita Tollstadius,
at +46 70 337 30 26.
###
About ContextVision
ContextVision is a medical technology company specializing in image analysis and
artificial intelligence. Its cutting-edge technology helps doctors accurately
interpret medical images, a crucial foundation for better diagnosis and
treatment. As an industry pioneer for more than 30 years, ContextVision is
taking a leading position within deep learning, the latest artificial
intelligence technology. ContextVision is currently investing significantly in
the field to expand its product portfolio. The present product portfolio
includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound,
MRI, X-ray and mammography which is used by leading equipment manufacturers
worldwide. ContextVision is based in Sweden and listed on the Oslo Stock
Exchange under the ticker COV. For more information, please visit
www.contextvision.com.
ContextVision Q4 and full year 2016 report:
http://hugin.info/134918/R/2080649/783771.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ContextVision AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 23.02.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 526014
Anzahl Zeichen: 4075
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ContextVision presents Q4 and full year 2016 report"
steht unter der journalistisch-redaktionellen Verantwortung von
ContextVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
